ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
(MENAFN- GetNews) The Key Complement 3 Glomerulopathy Companies in the market include - NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others. DelveInsight's ...
Wieme, R. J., Demeulenaere, L., and Segers, J., Prot. Biol. Fluids (Proc. Fifteenth Colloq., Bruges), 15, 499 (Elsevier, Amsterdam, 1968).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results